Recombinant VEGF (Bevacizumab Biosimilar) antibody
Reactivity: Human
FACS, in vivo
Host: Mouse
Monoclonal
unconjugated
Recombinant Antibody
-
- Target See all VEGF (Bevacizumab Biosimilar) products
- VEGF (Bevacizumab Biosimilar)
- Antibody Type
- Recombinant Antibody
- Reactivity
- Human
-
Host
- Mouse
-
Clonality
- Monoclonal
-
Conjugate
- This VEGF (Bevacizumab Biosimilar) antibody is un-conjugated
-
Application
- Flow Cytometry (FACS), In vivo Studies (in vivo)
- Purpose
- Bevacizumab Biosimilar, Human VEGF Monoclonal Antibody
- Specificity
- The monoclonal antibody Bevacizumab biosimilar specifically binds to the human VEGF-A.
- Characteristics
- Recombinant Humanized IgG1 Monoclonal Antibody generated from the same parent mouse antibody as ranibizumab.
- Purification
- Protein A affinity column
- Purity
- > 95% by SDS-PAGE under reducing conditions and HPLC.
- Sterility
- 0.2 μm filtered
- Endotoxin Level
- < 1 EU per 1 mg of the protein by the LAL method.
- Immunogen
- The monoclonal antibody Bevacizumab biosimilar was produced in the bevacizumab biosimilar CHO stable cell line.
- Isotype
- IgG1 kappa
-
-
- Application Notes
- ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by bevacizumab.
- Restrictions
- For Research Use only
-
- Format
- Liquid
- Concentration
- 1 mg/mL
- Buffer
- PBS, pH 7.4, no stabilizers or preservatives.
- Preservative
- Without preservative
- Handling Advice
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- Storage
- -20 °C
- Storage Comment
- 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
- Expiry Date
- 12 months
-
- Target
- VEGF (Bevacizumab Biosimilar)
- Abstract
- VEGF (Bevacizumab Biosimilar) Products
- Synonyms
- MVCD1 antibody, VEGF antibody, VPF antibody, vascular endothelial growth factor A antibody, VEGFA antibody
- Target Type
- Biosimilar
- Background
-
Bevacizumab, the humanized anti-VEGF-A monoclonal antibody, produces angiogenesis inhibition and slows the growth of new blood vessels. As the first clinically available angiogenesis inhibitor in the United States, Bevacizumab is used for treatment of certain metastatic cancers, certain lung cancers, renal cancers, ovarian cancers, breast cancers, and glioblastoma multiforme of the brain.
Vascular endothelial growth factor A (VEGF-A) stimulates angiogenesis in a variety of cancers, including colorectal, lung, breast, glioblastoma, kidney, and ovarian cancers.
-
You are here:
